Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

Open access
Choueiri, Toni K., Lim, Zita Dubauskas, Hirsch, Michelle S., Tamboli, Pheroze, Jonasch, Eric, McDermott, David F., Cin, Paola Dal, Corn, Paul, Vaishampayan, Ulka, Heng, Daniel Y.C., Tannir, Nizar M. · 2010 · Cancer

Abstract

BACKGROUND: Adult “translocation” renal cell carcinoma (RCC), bearing transcription factor E3 (TFE3) gene fusions at Xp11.2, is a recently recognized, unique entity for which prognosis and therapy remain poorly understood. In the current study, the authors investigated the effect of vascular endothelial growth factor (VEGF)‐targeted therapy in this distinct subtype of RCC. METHODS: A retrospective review was conducted to describe the clinical characteristics and outcome of adult patients with metastatic Xp11.2 RCC who had strong TFE3 nuclear immunostaining and received anti‐VEGF therapy. Tumor response to anti‐VEGF therapy was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The Kaplan‐Meier method was used to estimate progression‐free survival (PFS) and overall survival (OS) distributions. RESULTS: Fifteen patients were identified, of whom 10, 3, and 2 received sunitinib, sorafenib, and monoclonal anti‐VEGF antibodies, respectively. The median follow‐up was 19.1 months, the median age of the patients was 41 years, and the female:male ratio was 4:1. Initial histologic description included clear cell (n = 8 patients), papillary (n = 1 patient), or mixed clear cell/papillary RCC (n = 6 patients). Five patients had received prior systemic therapy. Five patients had undergone fluorescent in situ hybridization analysis and all demonstrated a translocation involving chromosome Xp11.2. When treated with VEGF‐targeted therapy, 3 patients achieved a partial response, 7 patients had stable disease, and 5 patients developed progressive disease. The median PFS and OS of the entire cohort were 7.1 months and 14.3 months, respectively. CONCLUSIONS: Adult‐onset, translocation‐associated metastatic RCC is an aggressive disease that affects a younger population of patients with a female predominance. In the current study, VEGF‐targeted agents appeared to demonstrate some efficacy. Cancer 2010. © 2010 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.25512

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 162

Metadata

Authors
Choueiri, T. K., Lim, Z. D., Hirsch, M. S., Tamboli, P., Jonasch, E., McDermott, D. F., Cin, P. D., Corn, P., Vaishampayan, U., Heng, D. Y. C., & Tannir, N. M.
Venue
Cancer
Publisher
Wiley
Published
2010-11-03
Volume
116
Issue
22
Pages
5219-5225
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2000438429
Cited by
162
References
1
FWCI
6.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. https://app.cochat.ai/papers/10.1002/cncr.25512
The paper
Choueiri, T. K., Lim, Z. D., Hirsch, M. S., Tamboli, P., Jonasch, E., McDermott, D. F., Cin, P. D., Corn, P., Vaishampayan, U., Heng, D. Y. C., & Tannir, N. M. (2010). Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. https://doi.org/10.1002/cncr.25512

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.